MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Other Current Assets · Q3 FY2026 · quarter ended Sep 2026
Other current assets rises 181.6% from a year ago
Other current assets stood at $2.48M at the end of Q3 FY2026, up 181.6% from a year earlier and up 113.4% from the prior quarter. Over 3 fiscal years it compounded at +117.2% a year.
Context
- Other current assets amounted to 0.5% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +181.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 861K USD
- Year-over-year change
- +7.2%
- 3-year CAGR
- +117.2%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 861K | +7.2% |
| FY2024 | 2024-12-31 | 803K | +503.8% |
| FY2023 | 2023-12-31 | 133K | +58.3% |
| FY2022 | 2022-12-31 | 84K | — |
Other Current Assets vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +181.6% is the highest of 7, against a peer median of +37.5%.
- Other current assets amounts to 0.5% of total assets for MBX, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $28.11M USD | +19.1% | +10.4% | 6.3% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $12.43M USD | — | — | 1.0% |
| Sep 2026 | €11.89M EUR | — | — | 0.5% | |
| Mar 2026 | $9.4M USD | +55.8% | +0.9% | 2.4% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $2.48M USD | +181.6% | +117.2% | 0.5% |
| Mar 2026 | $2.31M USD | +177.6% | +25.4% | 0.9% | |
| Mar 2026 | $1.63M USD | +83.2% | -22.3% | 3.5% | |
| Mar 2026 | $1.47M USD | -50.5% | -17.8% | 0.4% | |
| Jun 2026 | $941K USD | -66.6% | -39.5% | 0.2% | |
| Peer median (excluding MBX) | — | +37.5% | -8.4% | 0.9% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.